GlassScriptPhysician profile
Barry M Moss
NPI 1164404133
$5,054.30
in general payments reported to CMS, 2019-2025
32 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $112 · 2021: $752 · 2022: $865 · 2023: $887 · 2024: $647 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $729.62 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $699.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $581.15 | 2021-2025 | |
| Amgen INC. | $455.53 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $422.41 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.16 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Novartis Pharmaceuticals Corporation | $303.65 | 2019-2023 | |
| Glaxosmithkline, LLC. | $223.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $202.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.20 | 2021-2024 | |
| Esperion Therapeutics, INC. | $112.17 | 2021-2025 | Nexletol |
| Dexcom, INC. | $101.73 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $95.82 | 2021-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $75.90 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $71.71 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $65.61 | 2023-2024 | Onpattro, Givlaari |
| Exact Sciences Corporation | $54.23 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pulmonx Corporation | $43.13 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.35 | 2019-2022 | |
| Madrigal Pharmaceuticals | $31.27 | 2025 | Rezdiffra |
| Kowa Pharmaceuticals America, INC. | $29.20 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $20.76 | 2024 | Uptravi, Opsumit |
| Daiichi Sankyo INC. | $20.27 | 2024 | Injectafer |
| Eisai INC. | $20.08 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Amarin Pharma, INC. | $16.07 | 2020 | |
| Tolmar, INC. | $15.90 | 2025 | Jatenzo |
| Seqirus USA INC | $14.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2019 | |
| Inari Medical, INC. | $14.06 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bausch Health US, LLC | $13.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.